{"id":19310,"date":"2024-03-04T04:30:00","date_gmt":"2024-03-04T09:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-presentera-ses-resultats-financiers-pour-lexercice-2023-et-fera-le-point-sur-ses-activites-le-7-mars-2024\/"},"modified":"2024-03-08T10:07:41","modified_gmt":"2024-03-08T15:07:41","slug":"dbv-technologies-presentera-ses-resultats-financiers-pour-lexercice-2023-et-fera-le-point-sur-ses-activites-le-7-mars-2024","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-presentera-ses-resultats-financiers-pour-lexercice-2023-et-fera-le-point-sur-ses-activites-le-7-mars-2024\/","title":{"rendered":"DBV Technologies pr\u00e9sentera ses r\u00e9sultats financiers pour l\u2019exercice 2023 et fera le point sur ses activit\u00e9s le 7 mars 2024."},"content":{"rendered":"<div class=\"pr-date-globe\">March 04, 2024 16:30 ET<\/div>\n<p align=\"right\">Montrouge, France, le 4 mars &lpar;22h30 CET) 2024<\/p>\n<p align=\"justify\"><strong>DBV Technologies pr\u00e9sentera ses r\u00e9sultats financiers pour l\u2019exercice 2023 et fera le point sur ses activit\u00e9s le 7 mars 2024.<\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq Stock Market : DBVT), soci\u00e9t\u00e9 biopharmaceutique au stade clinique, a annonc\u00e9 aujourd\u2019hui que la soci\u00e9t\u00e9 organisera une conf\u00e9rence t\u00e9l\u00e9phonique et un webcast audio en direct le jeudi 7 mars \u00e0 23h00 &lpar;CET) afin de pr\u00e9senter les r\u00e9sultats financiers de l\u2019exercice 2023 et faire le point sur ses activit\u00e9s.<\/p>\n<p align=\"justify\">Les participants int\u00e9ress\u00e9s pourront acc\u00e9der \u00e0 cet appel en utilisant les num\u00e9ros de t\u00e9l\u00e9conf\u00e9rence ci-dessous et en demandant \u00e0 rejoindre l&rsquo;appel de DBV Technologies :<\/p>\n<p align=\"justify\">\u00c9tats-Unis :&nbsp;&nbsp; +1-844-481-2866<br \/>International : +1-412-317-1859<\/p>\n<p align=\"justify\">L\u2019appel sera diffus\u00e9 en direct sur le site web de la soci\u00e9t\u00e9, dans la section \u00ab Investisseurs \u00bb : <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fCAOWSg0yz5Za1jy_YEtSFHHW3R1UZkgm20AWkQWnYCET9dLD1aXJffk85Kn6ry6EI_jYqwY8XcGflweMvgBC9-fNVtzaGVCDmVDmn7xqVM6jK-q55M8yp3uL4GsbulBRruZi3sE56sEem87YZxFV2umvx1HFtTM603t0ZtBxAI=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/dbv-technologies.com\/fr\/investor-overview\/<\/a>. Une rediffusion de la pr\u00e9sentation sera \u00e9galement disponible sur le site web de DBV apr\u00e8s l\u2019\u00e9v\u00e9nement.<\/p>\n<p align=\"justify\"><strong>\u00c0 propos de DBV Technologies<\/strong><br \/>DBV Technologies d\u00e9veloppe Viaskin\u2122, une plateforme technologique exclusive exp\u00e9rimentale avec de larges applications potentielles en immunoth\u00e9rapie. Viaskin est bas\u00e9e sur l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e, ou EPIT\u2122, et constitue la m\u00e9thode de DBV Technologies pour d\u00e9livrer des compos\u00e9s biologiquement actifs au syst\u00e8me immunitaire \u00e0 travers la peau intacte. Avec cette nouvelle classe de produits candidats non invasifs, la Soci\u00e9t\u00e9 vise \u00e0 transformer en toute s\u00e9curit\u00e9 le traitement des patients souffrant d\u2019allergies alimentaires. Les programmes de DBV Technologies sur les allergies alimentaires comprennent des \u00e9tudes cliniques en cours sur Viaskin Peanut. Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Montrouge, en France, et ses op\u00e9rations nord-am\u00e9ricaines sont bas\u00e9es \u00e0 Basking Ridge, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Global Select Market &lpar;symbole : DBVT)<\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>Katie Matthews<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sXDO7kKO9U386HRNYwMce5FvH3Q7pGBmyyp8s_fgv6n2SGPRwdPR1iBM0eCA8G4u4nHIOIXoX8_XXo1_tt_DO3xZufI8mJHph7Al1hLdByYat1WEybnb0MZGZDi7MmpKB50buu1zqL_5sUpqblODIA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Aurora Krause<\/p>\n<p align=\"justify\">aurora.krause-ext@dbv-technologies.com<\/p>\n<p align=\"justify\">Viaskin et EPIT sont des marques commerciales de DBV Technologies.<\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=FW7Sxx_fxb0LUWePG2gWQm03NHs_k6ECeBjkev8JZIORcnGqB5PT8G4D1DINFNmMCmpDxlmBCOhPDTK8tyDl7CMwfNRaOlkDU8ptQmylzCT1e0I0T4TICVX8Qa646jxAGKNOL-E12AifEOGmKGFBVgEx8KoPSX79OR_wq3GApYs=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/MDc3Nzk4NDAtYWI2MS00MWVkLTk2ODUtNGMwYjA2OTg3NDkyLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[47],"class_list":["post-19310","press_releases","type-press_releases","status-publish","hentry","press_release_type-amf-filing"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/19310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/19310\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=19310"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=19310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}